

2021 CPT Updates

Changes effective January 01, 2021

Elizabeth Morales, CPC

Contents

E & M	
RADIOLOGY	2
NTERVENTIONAL RADIOLOGY	2
CARDIOLOGY	
ARDIOLOGY	
PATHOLOGY	11



E & M

The AMA has revised the Evaluation and Management code sets for year 2021. APS has highlighted the changes below:

- Code 99201 will be deleted.
- Clinicians may use either time or medical decision making to select a code.
- There will be no required level of history or exam for visits 99202-99215.
- MDM is driven by three elements, see section 2 for further information.
- All "time" used for leveling the E/M must be on the same day of encounter.
- Addition of a shorter 15-minute prolonged service code (99XXX)
 - •To be reported only when the visit is based on time and after the total time of the highest- level service (ie, 99205 or 99215) has been exceeded.
- 1. Time will be defined as total time spent, including non-face-to-face work done on that day, and will no longer require time to be dominated by counseling, see below chart.

	-
99202	Office or other outpatient visit for the evaluation and management of a new patient, which
	requires a medically appropriate history and/or examination and straightforward medical
	decision making. When using time for code selection, 15-29 minutes of total time is spent
	on the date of the encounter.
99203	Office or other outpatient visit for the evaluation and management of a new patient, which
	requires a medically appropriate history and/or examination and low level of medical
	decision making. When using time for code selection, 30-44 minutes of total time is spent
	on the date of the encounter.
99204	Office or other outpatient visit for the evaluation and management of a new patient, which
	requires a medically appropriate history and/or examination and moderate level of medical
	decision making. When using time for code selection, 45-59 minutes of total time is spent
	on the date of the encounter.
99205	Office or other outpatient visit for the evaluation and management of a new patient, which
	requires a medically appropriate history and/or examination and high level of medical
	decision making. When using time for code selection, 60-74 minutes of total time is spent
	on the date of the encounter.
99211	Office or other outpatient visit for the evaluation and management of an established
	patient, that may not require the presence of a physician or other qualified health care
	professional. Usually, the presenting problem(s) are minimal. (Time and MDM do not apply)
99212	Office or other outpatient visit for the evaluation and management of an established
	patient, which requires a medically appropriate history and/or examination and
	straightforward medical decision making. When using time for code selection, 10-19
	minutes of total time is spent on the date of the encounter.
	·

99213	Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and low level of medical decision making. When using time for code selection, 20-29 minutes of total time is spent on the date of the encounter.
99214	Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and moderate level of medical decision making. When using time for code selection, 30-39 minutes of total time is spent on the date of the encounter.
99215	Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and high level of medical decision making. When using time for code selection, 40-54 minutes of total time is spent on the date of the encounter.
+99XXX	Prolonged office or other outpatient evaluation and management service(s) (beyond the total time of the primary procedure which has been selected using total time), requiring total time or without direct patient contact beyond the usual service, on the date of the primary service; each 15 minutes (List separately in addition to codes 99205, 99215 for office or other outpatient Evaluation and Management services) (Use 99XXX in conjunction with 99205, 99215) (Do not report 99XXX in conjunction with 99354, 99335, 99358, 99359, 99415, 99416) (Do not report 99XXX for any time unit less than 15 minutes).

Activities included in total "time" can be located here.

- 2. Medical Decision-Making calculation is like, but not identical to, the current MDM calculations. The overall complexity of this calculation is driven by three elements:
 - The number and complexity of problems addressed
 - The amount and/or complexity of data to be reviewed and analyzed
 - The risk complications and/or morbidity or mortality of patient management

Please refer to the AMA chart for further information regarding how to level using MDM at AMA table .

Detailed information regarding 2021 E&M can be located here.



RADIOLOGY

СРТ	Description	Comments
• New	•	
△ Revised		
	Radiology	
• 0633T	Computed tomography, breast, including 3D rendering,	New set of unilateral
	when performed, unilateral; without contrast material	and bilateral breast CT
● 0634T	Computed tomography, breast, including 3D rendering,	scan Category III
	when performed, unilateral; with contrast material(s)	codes that are eligible
● 0635T	Computed tomography, breast, including 3D rendering,	for 2021 reporting. Up
	when performed, unilateral; without contrast, followed	until 2021, the CPT
	by contrast material(s)	code book has not
● 0636T	Computed tomography, breast, including 3D rendering,	included any codes, Category III or
	when performed, bilateral; without contrast material(s)	otherwise, for breast
● 0637T	Computed tomography, breast, including 3D rendering,	CT scan reporting. You
0000	when performed, bilateral; with contrast material(s)	will now have the
• 0638T	Computed tomography, breast, including 3D rendering,	option to report one
	when performed, bilateral; without contrast, followed by contrast material(s)	of two code sets,
	by contrast material(s)	depending on
		laterality.
		Furthermore, you do
		not need to worry
		about finding
		documentation to
		support optional 3D
		rendering.
△ 71250	Computed tomography, thorax, diagnostic; without	Revised to include
	contrast material	"diagnostic"
△ 71260	Computed tomography, thorax, diagnostic; with	
	contrast material(s)	
△ 71270	Computed tomography, thorax, diagnostic; without	
	contrast material, followed by contrast material(s) and	
	further sections	
• 71271	Computed tomography, thorax, low dose for lung	Based on the heavy
	cancer screening, without contrast material(s)	utilization of code
		G0297 in diagnostic
		radiology practices,
		the AMA followed



△ 74425	Urography, antegrade (pyelostogram, nephrostogram, loopogram), radiological supervision and interpretation	through on CPT Editorial Panel recommendations to create a permanent CPT Category I code for this service A reciprocal parenthetical will be added clarifying that it can be reported with codes 50390, 50396, 50684, and 50690.
2020 Deleted Radiology CPT Code(s) (effective 1/1/2021)		
G0297	Low dose CT scan (LDCT) for lung cancer screening	To report, see code 71271



INTERVENTIONAL RADIOLOGY

СРТ	Description		
• New			
△ Revised			
Interventional Radiology			
• 0620T	Endovascular venous arterialization, tibial or peroneal vein, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all		
	catheterization(s) and intraprocedural road mapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed		
• 32408	Core needle biopsy, lung, or mediastinum, percutaneous, including imaging guidance, when performed		
• 55880	Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance		
△ 64479	Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging guidance (fluoroscopy or CT), cervical or thoracic, single level		
△64480	Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging guidance (fluoroscopy or CT), cervical or thoracic, each additional level (List separately in addition to code for primary procedure)		
△ 64483	Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging guidance (fluoroscopy or CT), lumbar or sacral, single level		
△ 64484	64484 – Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging guidance (fluoroscopy or CT), lumbar or sacral, each additional level (List separately in addition to code for primary procedure)		
2020 Interventional Radiology Deleted CPT Codes (effective 1/1/2021)			
32405	Biopsy, lung or mediastinum, percutaneous needle		
0228T	Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with ultrasound guidance, cervical or thoracic, single level		



0229T	Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with ultrasound guidance, cervical or thoracic, each additional level (List separately in addition to code for primary procedure)
0230T	Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with ultrasound guidance, lumbar or sacral, single level
0231T	Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with ultrasound guidance, lumbar or sacral, each additional level (List separately in addition to code for primary procedure)



CARDIOLOGY

СРТ	Description	
●New		
△Revised		
●0623T	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission, computerized analysis of data, with review of computerized analysis output to reconcile discordant data, interpretation and report	
●0624T	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission	
●0625T	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; computerized analysis of data from coronary computed tomographic angiography	
●0626T	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; review of computerized analysis output to reconcile discordant data, interpretation and report	
●0627T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; first level	
+•0628T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; each additional level (List separately in addition to code for primary procedure)	
●0629T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; first level	
+•0630T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; each additional level (List separately in addition to code for primary procedure)	
●0631T	Transcutaneous visible light hyperspectral imaging measurement of oxyhemoglobin, deoxyhemoglobin, and tissue oxygenation, with interpretation and report, per extremity	



	T
●0632T	Percutaneous transcatheter ultrasound ablation of nerves innervating the
	pulmonary arteries, including right heart catheterization, pulmonary artery
	angiography, and all imaging guidance
●33741	Transcatheter atrial septostomy (TAS) for congenital cardiac anomalies to
	create effective atrial flow, including all imaging guidance by the
	proceduralist, when performed, any method (eg, Rashkind, Sang-Park,
	balloon, cutting balloon, blade)
●33745	Transcatheter intracardiac shunt (TIS) creation by stent placement for
	congenital cardiac anomalies to establish effective intracardiac flow,
	including all imaging guidance by the proceduralist, when performed, left
	and right heart diagnostic cardiac catherization for congenital cardiac
	anomalies, and target zone angioplasty, when performed (eg, atrial
	septum, Fontan fenestration, right ventricular outflow tract,
	Mustard/Senning/Warden baffles); initial intracardiac shunt
+●33746	Transcatheter intracardiac shunt (TIS) creation by stent placement for
	congenital cardiac anomalies to establish effective intracardiac flow,
	including all imaging guidance by the proceduralist, when performed, left
	and right heart diagnostic cardiac catherization for congenital cardiac
	anomalies, and target zone angioplasty, when performed (eg, atrial
	septum, Fontan fenestration, right ventricular outflow tract,
	Mustard/Senning/Warden baffles); each additional intracardiac shunt
	location (List separately in addition to code for primary procedure)
△33990	Insertion of ventricular assist device, percutaneous, including radiological
	supervision and interpretation; left heart, arterial access only
△33991	Insertion of ventricular assist device, percutaneous, including radiological
	supervision and interpretation; left heart, both arterial and venous access,
	with transseptal puncture
△33992	Removal of percutaneous left heart ventricular assist device, arterial or
	arterial and venous cannula(s), at separate and distinct session from
	insertion
△33993	Repositioning of percutaneous right or left heart ventricular assist device
	with imaging guidance at separate and distinct session from insertion
●33995	Insertion of ventricular assist device, percutaneous, including radiological
	supervision and interpretation; right heart, venous access only
●33997	Removal of percutaneous right heart ventricular assist device, venous
	cannula, at separate and distinct session from insertion
●93241	External electrocardiographic recording for more than 48 hours up to 7
	days by continuous rhythm recording and storage; includes recording,
	scanning analysis with report, review and interpretation
L	1 , , , , , , , , , , , , , , , , , , ,



●93242	External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; recording (includes connection and initial recording)		
•93243	External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; scanning analysis with report		
●93244	External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; review and interpretation		
●93245	External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; includes recording, scanning analysis with report, review, and interpretation		
●93246	External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording)		
●93247	External electrocardiographic recording by continuous rhythm recording and sto		
●93248	External electrocardiographic recording		
	by continuous rhythm recording and sto		
02057	2020 Deleted Cardiology CPT Codes		
0295T	External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; includes recording, scanning analysis with report, review, and interpretation	0295T 0296T 0297T 0298T	
0296T	External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; recording (includes connection and initial recording)		
0297T	External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; scanning analysis with report		



0298T	External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation	
0381T	External heart rate and 3-axis accelerometer data recording up to 14 days to assess changes in heart rate and to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; includes report, scanning analysis with report, review and interpretation by a physician or other qualified health care professional	0381T 0382T 0383T
0382T	External heart rate and 3-axis accelerometer data recording up to 14 days to assess changes in heart rate and to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; review and interpretation only	
0383T	External heart rate and 3-axis accelerometer data recording from 15 to 30 days to assess changes in heart rate and to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; includes report, scanning analysis with report, review and interpretation by a physician or other qualified health care professional	
l		



0384T	External heart rate and 3-axis accelerometer data recording from 15 to 30 days to assess changes in heart rate and to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; review and interpretation only External heart rate and 3-axis accelerometer data recording more than 30 days to assess changes in heart rate and to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; includes report, scanning analysis with report, review and interpretation by a physician or other qualified health care professional	0384T 0385T 0386T
0386T	External heart rate and 3-axis accelerometer data recording more than 30 days to assess changes in heart rate and to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; review and interpretation only	



PATHOLOGY

New A Revised Chorionic gonadotropin stimulation panel; testosterone response This panel must include the following: Testosterone (84403 x 2 on 3 pooled blood samples) △80415 Chorionic gonadotropin stimulation panel; estradiol response This panel must include the following: Estradiol, total (82670 x 2 on 3 pooled blood samples) ●81168 CCND1/IGH (t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative and quantitative, if performed ●81191 NTRK1 (neurotrophic receptor tyrosine kinase 1) (eg, solid tumors) translocation analysis ●81192 NTRK2 (neurotrophic receptor tyrosine kinase 2) (eg, solid tumors) translocation analysis ●81193 NTRK3 (neurotrophic receptor tyrosine kinase 3) (eg, solid tumors) translocation analysis ●81194 NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis ●81194 NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis ●81194 NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis ●81278 IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint recipion (mcr) breakpoints, qualitative or quantitative ●81278 JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) trageted sequence analysis (eg, exons 12 and 13) ●81279 JAK2 (Janus kinase 2) (eg, Myeloproli	СРТ	Description
Δ Revised Chorionic gonadotropin stimulation panel; testosterone response This panel must include the following: Testosterone (84403 x 2 on 3 pooled blood samples) △80415 Chorionic gonadotropin stimulation panel; estradiol response This panel must include the following: Estradiol, total (82670 x 2 on 3 pooled blood samples) ◆81168 CCND1/IGH (t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative and quantitative, if performed ◆81191 NTRK1 (neurotrophic receptor tyrosine kinase 1) (eg, solid tumors) translocation analysis ◆81192 NTRK2 (neurotrophic receptor tyrosine kinase 2) (eg, solid tumors) translocation analysis ◆81193 NTRK3 (neurotrophic receptor tyrosine kinase 3) (eg, solid tumors) translocation analysis ◆81194 NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis ◆81278 IGH@/BCL2 (t(14;13)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative ◆81279 JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13) ◆81338 MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515k, W515k) ◆81339 MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, P52L, P52L)<		
△80414 Chorionic gonadotropin stimulation panel; testosterone response This panel must include the following: Testosterone (84403 x 2 on 3 pooled blood samples) △80415 Chorionic gonadotropin stimulation panel; estradiol response This panel must include the following: Estradiol, total (82670 x 2 on 3 pooled blood samples) ●81168 CCND1/IGH (t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative and quantitative, if performed ●81191 NTRK1 (neurotrophic receptor tyrosine kinase 1) (eg, solid tumors) translocation analysis ●81192 NTRK2 (neurotrophic receptor tyrosine kinase 2) (eg, solid tumors) translocation analysis ●81193 NTRK3 (neurotrophic receptor tyrosine kinase 3) (eg, solid tumors) translocation analysis ●81194 NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis ●81278 IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative ●81279 JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13) ●81338 MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R) ●81339 MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P55H, P		
 △80415 Chorionic gonadotropin stimulation panel; estradiol response This panel must include the following: Estradiol, total (82670 x 2 on 3 pooled blood samples) ●81168 CCND1/IGH (t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative and quantitative, if performed ●81191 NTRK1 (neurotrophic receptor tyrosine kinase 1) (eg, solid tumors) translocation analysis ●81192 NTRK2 (neurotrophic receptor tyrosine kinase 2) (eg, solid tumors) translocation analysis ●81193 NTRK3 (neurotrophic receptor tyrosine kinase 3) (eg, solid tumors) translocation analysis ●81194 NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis ●81278 IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative ●81279 JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13) ●81338 MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R) ●81339 MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10 ●81347 SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L) ●81351 TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; trageted sequence analysis (eg, 4 oncology) ●81352 TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; trageted sequence analysis (eg, 4 oncology) ●81353 TP53 (tumor protein 53) (eg, Receptor Acute myeloid leukemia) gene analysis; common variants (eg, S34F, S34Y, Q157R, Q157P) ●81360 ZRSR2 (zinc fin		Chorionic gonadotropin stimulation panel; testosterone response This panel must
the following: Estradiol, total (82670 x 2 on 3 pooled blood samples) 81168		
 CCND1/IGH (t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative and quantitative, if performed NTRK1 (neurotrophic receptor tyrosine kinase 1) (eg, solid tumors) translocation analysis NTRK2 (neurotrophic receptor tyrosine kinase 2) (eg, solid tumors) translocation analysis NTRK3 (neurotrophic receptor tyrosine kinase 3) (eg, solid tumors) translocation analysis NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13) MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R) MB1339 MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10 SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L) SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; targeted sequence analysis (eg, 4 oncology) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; targeted sequence analysis (eg, 4 oncology) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant V2AF1 (U2 small nuclear RN	△80415	Chorionic gonadotropin stimulation panel; estradiol response This panel must include
breakpoint, qualitative and quantitative, if performed NTRK1 (neurotrophic receptor tyrosine kinase 1) (eg, solid tumors) translocation analysis NTRK2 (neurotrophic receptor tyrosine kinase 2) (eg, solid tumors) translocation analysis NTRK3 (neurotrophic receptor tyrosine kinase 3) (eg, solid tumors) translocation analysis NTRK3 (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis; comid leukerial gene (mcr) breakpoints, qualitative or quantitative NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis; emplorable fireative disorder) translocation analysis (eg, exons 12 and 13) NTRK (neurotrophic receptor tyrosine kinase 2) (eg, solid tumors) translocation analysis (eg, epomple fireative disorder) translocation analysis; emploritative disorder) translocation analysis; egmene analysis; egmene protein receptor) (eg, myelodyroplaferative disorder) gene analysis; sequence analysis, exon 10 NTRK (neurotrophic receptor tyrosine kinase 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, M515A, W515A, W515		the following: Estradiol, total (82670 x 2 on 3 pooled blood samples)
 NTRK1 (neurotrophic receptor tyrosine kinase 1) (eg, solid tumors) translocation analysis NTRK2 (neurotrophic receptor tyrosine kinase 2) (eg, solid tumors) translocation analysis NTRK3 (neurotrophic receptor tyrosine kinase 3) (eg, solid tumors) translocation analysis NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13) MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R) MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10 S7381 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L) SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; targeted sequence analysis (eg, 4 oncology) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant V2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leu	●81168	CCND1/IGH (t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major
 analysis NTRK2 (neurotrophic receptor tyrosine kinase 2) (eg, solid tumors) translocation analysis NTRK3 (neurotrophic receptor tyrosine kinase 3) (eg, solid tumors) translocation analysis NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative JAK2 (lanus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13) MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R) MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10 SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L) SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence analysis (eg, 4 oncology) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs) 		breakpoint, qualitative and quantitative, if performed
 NTRK2 (neurotrophic receptor tyrosine kinase 2) (eg, solid tumors) translocation analysis NTRK3 (neurotrophic receptor tyrosine kinase 3) (eg, solid tumors) translocation analysis NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13) MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R) MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10 SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L) SR5F2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence analysis (eg, 4 oncology) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant V2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs) 	●81191	NTRK1 (neurotrophic receptor tyrosine kinase 1) (eg, solid tumors) translocation
 analysis NTRK3 (neurotrophic receptor tyrosine kinase 3) (eg, solid tumors) translocation analysis NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13) MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R) MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10 SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L) SR5F2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; targeted sequence analysis (eg, 4 oncology) P53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant V2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) R81360 ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) 		analysis
 NTRK3 (neurotrophic receptor tyrosine kinase 3) (eg, solid tumors) translocation analysis NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13) MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R) MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10 SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L) SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence analysis (eg, 4 oncology) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs) 	●81192	NTRK2 (neurotrophic receptor tyrosine kinase 2) (eg, solid tumors) translocation
 analysis NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13) MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R) MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10 SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L) SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence analysis (eg, 4 oncology) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants(s) (eg, E65fs, E122fs, R448fs) 		·
 NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13) MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R) MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10 SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L) SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence analysis (eg, 4 oncology) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs) 	●81193	1
translocation analysis IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative IGH@/BCL2 (t(14;18)) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13) IGH@/BCL2 (tog, myeloproliferative disorder) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R) IGH@/BCL2 (tog)		· ·
 IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13) MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R) MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10 SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L) SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence analysis (eg, 4 oncology) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants(s) (eg, E65fs, E122fs, R448fs) 	●81194	
region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative ### MRE (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13) ###################################		·
 881279 JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13) 881338 MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R) 881339 MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10 881347 SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L) 881348 SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L) 881351 TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence analysis (eg, 4 oncology) 881352 TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant 881357 U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) 881360 ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs) 	●81278	
 exons 12 and 13) MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R) MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10 SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L) SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; targeted sequence analysis (eg, 4 oncology) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs) 		
 MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R) MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10 SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L) SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence analysis (eg, 4 oncology) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs) 	●81279	
gene analysis; common variants (eg, W515A, W515K, W515L, W515R) •81339 MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10 •81347 SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L) •81348 SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L) •81351 TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence analysis (eg, 4 oncology) •81352 TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant •81353 U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) •81360 ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs)		·
 MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10 SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L) SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence analysis (eg, 4 oncology) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs) 	●81338	
gene analysis; sequence analysis, exon 10 SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L) SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence analysis (eg, 4 oncology) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloidysplastic syndrome, acute myeloid leukemia) gene analysis, common variants) (eg, E65fs, E122fs, R448fs)		
 \$81347 SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L) \$81348 SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L) \$81351 TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence \$81352 TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; targeted sequence analysis (eg, 4 oncology) \$81353 TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant \$81357 U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) \$81360 ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs) 	●81339	
leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L) SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence analysis (eg, 4 oncology) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; targeted sequence analysis (eg, 4 oncology) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs)		
 SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; targeted sequence analysis (eg, 4 oncology) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs) 	●81347	
 myeloid leukemia) gene analysis, common variants (eg, P95H, P95L) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; targeted sequence analysis (eg, 4 oncology) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs) 	. 04040	
 TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; targeted sequence analysis (eg, 4 oncology) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs) 	●81348	
 ◆81352 TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; targeted sequence analysis (eg, 4 oncology) ◆81353 TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant ◆81357 U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) ◆81360 ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs) 	•01251	
 analysis (eg, 4 oncology) TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs) 		
●81353 TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant ●81357 U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) ■81360 ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs)	●81352	
•81357 U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) •81360 ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs)	-01252	1
●81357 U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) ■81360 ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs)	●81353	
myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) 2RSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs)	•012F7	
●81360 ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs)	●81357	
myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs)	■81360	
(eg, E65fs, E122fs, R448fs)	-01300	
△81401 MOLECULAR PATHOLOGY PROCEDURF FVFI 2	△81401	MOLECULAR PATHOLOGY PROCEDURE LEVEL 2
△81402 MOLECULAR PATHOLOGY PROCEDURE LEVEL 3		
△81403 MOLECULAR PATHOLOGY PROCEDURE LEVEL 4		



△81404	MOLECULAR PATHOLOGY PROCEDURE LEVEL 5	
△81405	MOLECULAR PATHOLOGY PROCEDURE LEVEL	
●81419	Epilepsy genomic sequence analysis panel, must include analyses for ALDH7A1, CACNA1A, CDKL5, CHD2, GABRG2, GRIN2A, KCNQ2, MECP2, PCDH19, POLG, PRRT2, SCN1A, SCN1B, SCN2A, SCN8A, SLC2A1, SLC9A6, STXBP1, SYNGAP1, TCF4, TPP1, TSC1, TSC2, and ZEB2	
●81513	Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis	
●81514	Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers for Gardnerella vaginalis, Atopobium vaginae, Megasphaera type 1, Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), and Lactobacillus species (L. crispatus and L. jensenii), utilizing vaginal-fluid specimens, algorithm reported as a positive or negative for high likelihood of bacterial vaginosis, includes separate detection of Trichomonas vaginalis and/or Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata, Candida krusei, when reported	
●81529	Oncology (cutaneous melanoma), mRNA, gene expression profiling by real-time RT-PCR of 31 genes (28 content and 3 housekeeping), utilizing formalin-fixed paraffinembedded tissue, algorithm reported as recurrence risk, including likelihood of sentinel lymph node metastasis	
●81546	Oncology (thyroid), mRNA, gene expression analysis of 10,196 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (eg, benign or suspicious)	
●81554	Pulmonary disease (idiopathic pulmonary fibrosis [IPF]), mRNA, gene expression analysis of 190 genes, utilizing transbronchial biopsies, diagnostic algorithm reported as categorical result (eg, positive or negative for high probability of usual interstitial pneumonia [UIP])	
●82077	Alcohol (ethanol); any specimen except urine and breath, immunoassay (eg, IA, EIA, ELISA, RIA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)	
●82681	Estradiol; free, direct measurement (eg, equilibrium dialysis)	
2020 Deleted Pathology CPT Code(s) (effective 1/1/2021)		
81545	Oncology (thyroid), gene expression analysis of 142 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (eg, benign or suspicious)	

